Memory T-cell-specific therapeutics attenuate allograft rejection via mediation of alloreactivity in memory cells.
Many means in inbred rodent models promoted long-term graft survival or donor-specific tolerance, but less so in nonhuman primates, outbred rodents or human patients. A diverse repertoire of memory T cells, derived from heterologous immunity or prior to exposure to alloantigen, has been believed to be an important part of this barrier. Memory T cells have a unique capacity to generate effector functions quickly upon re-exposure to antigen, and this capacity is achieved by reduced activation thresholds, and expressed high level trafficking and adhesion molecules, which is likely responsible for their exhibiting differential susceptibility to immune therapeutics compared with naïve T cells. This review outlines recent progress on characteristics of memory T cells and focuses on these potential therapies targeting memory T cells which are likely to ameliorate allograft rejection by inducing transplant tolerance.
Department of Research and Education, Guizhou Province People's Hospital, Guiyang, China.
Lei
L
Luo
Zhaolin
Z
Sun
Hui
H
Cheng
Guangheng
G
Luo
D003713:Dendritic Cells / Q000276:immunology; D006084:Graft Rejection / Q000276:immunology* / Q000517:prevention & control; D006801:Humans; D007156:Immunologic Memory / Q000276:immunology*; D007166:Immunosuppressive Agents / Q000276:immunology / Q000627:therapeutic use; D007519:Isoantigens / Q000276:immunology; D018448:Models, Immunological; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology* / Q000378:metabolism; D023001:Transplantation Tolerance / Q000276:immunology*; D014184:Transplantation, Homologous
D007166:Immunosuppressive Agents; D007519:Isoantigens